Arbutus Biopharma completes US$230M modified Dutch auction substantial issuer bid and tender offer

On October 5, 2026, Arbutus Biopharma Corporation (“Arbutus”) announced the final results of its modified Dutch auction substantial issuer bid and tender offer to purchase for cancellation up to US$230 million of its common shares. Following the expiry of the offer on September 29, 2026, Arbutus took up and purchased 46,000,000 common shares at a purchase price of US$5.00 per share, for an aggregate purchase price of US$230 million, representing approximately 23% of its issued and outstanding common shares.

Arbutus is a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania, focused on developing treatments for infectious diseases.

McCarthy Tétrault LLP acted as Canadian counsel to Arbutus in connection with the tender offer with a team led by Raj Juneja and Gerald Gaunt, and that included David Frost, Thomas Fung, Alessandra Davoli, Charles-Antoine Soulière, Stéphanie Beaudoin, Andrew Parker, Michael Bennett, Kyle Barretto, Liam Peet-Pare, (Business), Jeremy Ho, Darren Chung (Tax), Carine Trudel, Laurence Gauthier, Anabel Lopez, Marie-Eve Bédard (MT>Version), Sharon Kretchmar, Angela Lizotte (Law Clerk), Melissa Furlong (Paralegal) and Lauren Tse (Summer Student).